Optimal Adjuvant Intravesical Therapy for Intermediate Risk Non Muscle Invasive Bladder Cancer: A Randomized Controlled Trial

• Status: Not yet recruiting
• Trial end date: 2023-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this prospective, single-center randomized controlled trial is to identify the optimal adjuvant intravesical therapy in patients with intermediate risk (IR) non muscle invasive bladder cancer by comparing two commonly utilized intravesical regimens; intravesical immunotherapy (BCG) and intravesical chemotherapy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mansoura University
• Treatments: Epirubicin

Criteria

Inclusion Criteria:

• 1- Adult patients (aged >18 years) 2- Patients with primary or recurrent papillary NMIBC. 3- Complete TURBT. 4- Patients with IR NMIBC confirmed by histopathology.

Exclusion Criteria:

• 1. Inability to give informed consent. 2. Patients with history of previous radiotherapy or systemic chemotherapy. 3. Patients suffering from immuno-deficiency or other malignancies. 4. Patients with history of hypersensitivity reaction to BCG or epirubicin. 5. Examination under anesthesia (EUA) reveals palpable bladder mass. 6. Patients with low or high risk NMIBC by histopathology